CytomX Therapeutics, Inc. (CTMX)
| Market Cap | 444.73M -36.0% |
| Revenue (ttm) | 14.03M -87.7% |
| Net Income | -88.42M |
| EPS | -0.45 |
| Shares Out | 218.00M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,724,695 |
| Open | 2.020 |
| Previous Close | 2.040 |
| Day's Range | 1.960 - 2.125 |
| 52-Week Range | 1.900 - 8.210 |
| Beta | 2.24 |
| Analysts | Strong Buy |
| Price Target | 12.38 (+506.86%) |
| Earnings Date | Nov 5, 2026 |
About CTMX
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclin... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for CTMX stock is "Strong Buy." The 12-month stock price target is $12.38, which is an increase of 506.86% from the latest price.
News
CytomX Therapeutics price target raised to $12 from $11 at JPMorgan
JPMorgan analyst Anupam Rama raised the firm’s price target on CytomX Therapeutics (CTMX) to $12 from $11 and keeps an Overweight rating on the shares. The firm updated the company’s…
CytomX Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
Varseta-M reported 20%-30% response rates and 6-7 months’ PFS in 4L+ CRC, with Grade 3 diarrhea declining in optimization cohorts. A Jan 2027 update is expected to include OS, optimization safety/ORR/PFS and pivotal-study direction.
CytomX Therapeutics price target raised to $12 from $11 at Wedbush
Wedbush raised the firm’s price target on CytomX Therapeutics (CTMX) to $12 from $11 and keeps an Outperform rating on the shares following quarterly results and corporate update. The firm…
CytomX Therapeutics Earnings Call Transcript: Q3 2026
Varseta-M is progressing toward a potential H1 2027 registrational study, with January data expected to inform dose selection and strategy. Q3 revenue fell as the Astellas collaboration ended, while quarter-end cash and investments were $348M and runway extends into H2 2028.
CytomX Therapeutics Quarterly report: Q3 2026
CytomX Therapeutics has published its Q3 2026 quarterly earnings report on November 5, 2026.
CytomX Therapeutics Earnings release: Q3 2026
CytomX Therapeutics released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
CytomX Therapeutics reports Q3 EPS (9c), consensus (7c)
Reports Q3 revenue $1.688M vs $5.963M last year. “Varseta-M is a first-in-class EpCAM-directed antibody drug conjugate with a topoisomerase-1 inhibitor payload, intentionally designed to improve the s...
CytomX Therapeutics announces cash runway into 2H of 2028
CytomX ended Q3 2026 with $348M of cash, cash equivalents and investments with expected cash runway into the second half of 2028. Cash, cash equivalents and short-term investments totaled $330.3…
CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update
- Varsetatug masetecan (Varseta-M) granted FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer - - Phase 1 monotherapy data update in metastatic colorectal cancer (mCRC) ex...
CytomX Therapeutics to Present at Upcoming November Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that manage...
CytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it wil...
CytomX Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Varseta-M showed 20%-30% response rates and estimated 6-7-month PFS in fourth-line-or-later CRC, with GI toxicity mitigation and registration planning underway. Bevacizumab combination data are expected in H1 2027, and cash runway extends to at least H2 2028.
CytomX Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Varseta-M showed 20%-30% ORR and 6-7-month PFS in late-line CRC, informing dose selection and a potential randomized OS-led pivotal study. Year-end 2026 data and H1 2027 combination and CX-801 updates are planned.
CytomX Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
Varseta-M, a first-in-class EpCAM-targeting ADC, is advancing rapidly in late-line colorectal cancer with Fast Track FDA status, promising efficacy, and a favorable safety profile. Combination and expansion studies are underway, while CX-801, a masked interferon alfa-2b, is progressing in late-line melanoma with encouraging early biomarker data.
CytomX Therapeutics Slides: Wells Fargo 21st Annual Healthcare Conference
CytomX Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 8, 2026.
CytomX Therapeutics to Present at Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that manag...
CytomX Therapeutics gets Fast Track Designation for Varseta-M
CytomX Therapeutics (CTMX) announced that the FDA has granted Fast Track Designation to Varseta-M for the treatment of patients with relapsed/refractory metastatic colorectal cancer. Varseta-M is an a...
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
- Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in 1H 2...
CytomX Therapeutics price target lowered to $11 from $12 at JPMorgan
JPMorgan lowered the firm’s price target on CytomX Therapeutics (CTMX) to $11 from $12 and keeps an Overweight rating on the shares.
CytomX Therapeutics price target lowered to $14 from $15 at Guggenheim
Guggenheim analyst Michael Schmidt lowered the firm’s price target on CytomX Therapeutics (CTMX) to $14 from $15 and keeps a Buy rating on the shares following the Q2 update focusing…
CytomX Therapeutics reports Q2 EPS (9c), consensus (10c)
Reports Q2 revenue $1.42M, consensus $12.34M. “CytomX had a productive second quarter as we advanced and broadened the Varseta-M program, the only EpCAM-directed antibody drug conjugate (ADC) in clini...
CytomX Therapeutics Earnings Call Transcript: Q2 2026
Varseta-M's development in CRC and other GI cancers advanced with strong clinical and operational progress, while financials reflect a robust cash position and increased R&D investment. Key milestones include a major Regeneron collaboration expansion and new executive hires.
CytomX Therapeutics Quarterly report: Q2 2026
CytomX Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
CytomX Therapeutics Earnings release: Q2 2026
CytomX Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
Varsetatug masetecan (“Varseta-M”) Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 - - Pha...